JP2021527061A5 - - Google Patents

Info

Publication number
JP2021527061A5
JP2021527061A5 JP2020567972A JP2020567972A JP2021527061A5 JP 2021527061 A5 JP2021527061 A5 JP 2021527061A5 JP 2020567972 A JP2020567972 A JP 2020567972A JP 2020567972 A JP2020567972 A JP 2020567972A JP 2021527061 A5 JP2021527061 A5 JP 2021527061A5
Authority
JP
Japan
Prior art keywords
dione
ethoxy
phenyl
methyl
syndrome
Prior art date
Application number
JP2020567972A
Other languages
English (en)
Japanese (ja)
Other versions
JP7510170B2 (ja
JPWO2019234690A5 (https=
JP2021527061A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/054744 external-priority patent/WO2019234690A1/en
Publication of JP2021527061A publication Critical patent/JP2021527061A/ja
Publication of JPWO2019234690A5 publication Critical patent/JPWO2019234690A5/ja
Publication of JP2021527061A5 publication Critical patent/JP2021527061A5/ja
Application granted granted Critical
Publication of JP7510170B2 publication Critical patent/JP7510170B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020567972A 2018-06-06 2019-06-06 5-[[4-[2-[5-アセチルピリジン-2-イル]エトキシ]ベンジル]-1,3-チアゾリジン-2,4-ジオンおよびその塩の使用 Active JP7510170B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18382402 2018-06-06
EP18382402.8 2018-06-06
PCT/IB2019/054744 WO2019234690A1 (en) 2018-06-06 2019-06-06 Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts

Publications (4)

Publication Number Publication Date
JP2021527061A JP2021527061A (ja) 2021-10-11
JPWO2019234690A5 JPWO2019234690A5 (https=) 2022-06-14
JP2021527061A5 true JP2021527061A5 (https=) 2022-06-14
JP7510170B2 JP7510170B2 (ja) 2024-07-03

Family

ID=62716011

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020567972A Active JP7510170B2 (ja) 2018-06-06 2019-06-06 5-[[4-[2-[5-アセチルピリジン-2-イル]エトキシ]ベンジル]-1,3-チアゾリジン-2,4-ジオンおよびその塩の使用

Country Status (14)

Country Link
US (2) US20210228558A1 (https=)
EP (1) EP3801517A1 (https=)
JP (1) JP7510170B2 (https=)
KR (1) KR20210031867A (https=)
CN (1) CN112823004A (https=)
AU (1) AU2019283650A1 (https=)
BR (1) BR112020024939A2 (https=)
CA (1) CA3102584A1 (https=)
CL (1) CL2020003163A1 (https=)
EA (1) EA202092954A1 (https=)
IL (1) IL279186A (https=)
MX (1) MX2020013182A (https=)
SG (1) SG11202012095XA (https=)
WO (1) WO2019234690A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
FI3801515T3 (fi) 2018-06-06 2025-05-27 Minoryx Therapeutics S L 5-[[4-[2-[5-(1-hydroksietyyli)pyridin-2-yyli]etoksi]fenyyli]metyyli]-1,3-tiatsolidiini-2,4-dionia ja sen suoloja käytettäviksi mitokondriosairauksien hoidossa
EP4142720A1 (en) * 2020-04-30 2023-03-08 Minoryx Therapeutics S.L. Leriglitazone for treating lung inflammation and interstitial lung disease
CN117769418A (zh) * 2021-05-19 2024-03-26 爱博利瓦有限公司 Kl1333用于医疗
MX2025013233A (es) * 2023-05-09 2026-02-03 Minoryx Therapeutics S L Formas polimorficas y formulaciones de leriglitazona

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0639229B2 (en) 1992-04-30 2009-11-25 Institut Pasteur Rapid detection of antibiotic resistance in mycobacterium tuberculosis
GB0030845D0 (en) * 2000-12-18 2001-01-31 Smithkline Beecham Plc Novel treatment
GB0510469D0 (en) * 2005-05-23 2005-06-29 Leuven K U Res & Dev Insulin sensitization to slow down pubertal tempo and to augment pubertal growth
AU2012203941A1 (en) * 2006-06-27 2012-07-26 Sandoz Ag New method for salt preparation
WO2008000418A2 (en) * 2006-06-27 2008-01-03 Sandoz Ag New method for salt preparation
WO2013040419A1 (en) * 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating hyperprolinemia-associated mental disorders
CA2941562C (en) 2013-03-14 2021-09-21 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
EP3125888B1 (en) 2014-04-02 2018-05-23 Minoryx Therapeutics S.L. 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
WO2017083739A1 (en) * 2015-11-13 2017-05-18 The Trustees Of Columbia University In The City Of New York A method for predicting a subject's response to valproic acid therapy
EP3559010B1 (en) 2016-12-23 2022-06-08 Minoryx Therapeutics S.L. Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof

Similar Documents

Publication Publication Date Title
JP2021527061A5 (https=)
JP2021527045A5 (https=)
US8202905B2 (en) Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof
EP4309738A2 (en) Method of treating medulloblastoma with an ezh2 inhibitor
US20100076037A1 (en) Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma
JP7510170B2 (ja) 5-[[4-[2-[5-アセチルピリジン-2-イル]エトキシ]ベンジル]-1,3-チアゾリジン-2,4-ジオンおよびその塩の使用
EP3280405B1 (en) Inhibitors and their uses
JP7549344B2 (ja) 治療有効量の5-[[4-[2-[5-(1-ヒドロキシエチル)ピリジン-2-イル]エトキシ]フェニル]メチル]-1,3-チアゾリジン-2,4-ジオンを投与する方法
JP2022059650A (ja) 筋萎縮性側索硬化症治療剤及び治療用組成物
US20250064791A1 (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases
US12102644B2 (en) Compounds and methods of promoting myelination
US5462965A (en) Use of heterocyclic amino-alcohol compounds for treatment of CNS diseases
EP3044192B1 (en) Deuterated compounds
JPWO2019234690A5 (https=)
JPWO2019234689A5 (https=)
US6288108B1 (en) Methods for increasing levels of acetylcholine
US20260053777A1 (en) Use of nrf2 activators for the treatment of cerebral small vessel disease
HK40049546A (en) Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
HK40042762A (en) Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts
WO2024245371A1 (zh) 一种组合产品、盐及其用于治疗神经退行性疾病或病症的用途
EA047194B1 (ru) Применение 5-[4-[2-[5-ацетилпиридин-2-ил]этокси]бензил]-1,3-тиазолидин-2,4-диона и его солей
JPWO2023147312A5 (https=)
WO2024078553A1 (zh) 治疗尘肺病的方法
US20110178100A1 (en) Apoptosis inhibitor
EA047277B1 (ru) Способ введения терапевтически эффективного количества 5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-диона